trending Market Intelligence /marketintelligence/en/news-insights/trending/MwbPkZgsITR0qBdN1gYltA2 content esgSubNav
In This List

Loxo Oncology starts rolling submission of FDA application for cancer drug

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Loxo Oncology starts rolling submission of FDA application for cancer drug

Loxo Oncology Inc. initiated the submission of a rolling new drug application to the U.S. Food and Drug Administration for its cancer treatment larotrectinib.

Larotrectinib is intended for treating unresectable or metastatic solid tumors with NTRK-fusion proteins in patients who require systemic therapy and have either progressed following prior treatment or have no acceptable alternative treatments.

The company expects to complete the submission in early 2018.